Expected timeline based on research: Initial vascular effects may begin within the first week
In the trial mentioned above, one year after stopping the GLP-1 medication, participants also saw: Blood pressure levels go back up C-reactive protein levels (an indicator of inflammation) increase VLDL cholesterol (a type that leads to hardened arteries) goes up Triglycerides (a type of blood fat) go up Hemoglobin A1c increases (meaning the level of sugar in the blood) At high levels, these health markers are associated with conditions like type 2 diabetes, obesity, hypertension, and heart disease, to list a few
When you make the retina more hypoxic, which is what the GLP-1s do, it basically pushes it further over the threshold, causing more abnormal blood vessels to grow, said Linda Lam, MD, MBA, an ophthalmologist with Keck Medicine of USC, who wasnt involved in the research
Baseline renal function was normal or mildly impaired in 88% of patients and moderately impaired in 11% of patients (mean eGFR 82 mL/min/1.73 m2)
Because topical research uses concentration-based dosing rather than absolute-mass dosing, the researcher must formulate the peptide into a carrier base at a target concentration, then apply a consistent volume to the research area